Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moga-CHOP-14 for untreated elderly CCR4-positive aggressive ATL
jRCTs041180130Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mogamulizumab in adult T-cell leukemia-lymphoma (ATLL), sponsored by Kyowa Kirin. Primary endpoint: 1-year progression-free survival. Started Nov 2015; status: completed.
02
Drugs
mogamulizumab
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCTs041180130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180130.